Literature DB >> 18415621

[Treatment of trigeminal neuralgia with vincristine iontophoresis. A clinical pilot study.].

H A Vogel1, R A Richter, I Albrecht, G Löwicke, F Klingberg.   

Abstract

Treatment of chronic pain disease is a scientific and clinical challenge encountered in all branches of medicine. Essential trigeminal neuralgia and chronic pain situations are noted for their exceptionally marked severity and also for their psychic and social consequences. It is not rare for a primarily somatic pain syndrome to develop into a painful disease in its own right, which is highly refractory to treatment. In transcutaneous iontophoresis of vincristine the neurotoxic effect of the alkaloid is employed locally and in a controlled manner. Iontophoresis of a microtubule inhibitor (vincristine, vinblastin) to the skin induces transganglionic degenerative atrophy of the central terminals of primary sensory neurons. Vincristine iontophoresis was applied in 33 patients hitherto unsuccessfully treated with various other methods. In 78% of the cases, attenuation of the pain was achieved. This noninvasive therapy proved to be free of side effects.

Entities:  

Year:  1992        PMID: 18415621     DOI: 10.1007/BF02528132

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  4 in total

1.  [Psychology of the pain experience].

Authors:  M Bullinger; W Keeser; E Pöppel
Journal:  Internist (Berl)       Date:  1986-07       Impact factor: 0.743

2.  Functional impairment of the primary nociceptive analyser in the course of transganglionic degenerative atrophy.

Authors:  A Szücs; B Csillik; E Knyihár-Csillik
Journal:  Acta Biol Hung       Date:  1983

3.  Treatment of terminal pain in cancer patients by means of iontophoresis of vinca alkaloids.

Authors:  A Szücs; B Csillik; E Knyihár-Csillik
Journal:  Recent Results Cancer Res       Date:  1984

4.  Iontophoretically applied microtubule inhibitors induce transganglionic degenerative atrophy of primary central nociceptive terminals and abolish chronic autochtonous pain.

Authors:  E Knyihár-Csillik; A Szücs; B Csillik
Journal:  Acta Neurol Scand       Date:  1982-10       Impact factor: 3.209

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.